EPA + DHA supplements: Participants will randomly assigned to the supplemented group. The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg EPA + DHA
Placebo: Participants will randomly assigned to the Placebo group. The placebo will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg MCT.
Study summary
The aim of this study is to evaluate the effects of omega-3 fatty acid supplementation on the Omega-3 Index, erythrocyte membrane composition, cognitive function, hormonal profile, speed, endurance performance, and hematological parameters in competitive athletes aged 16-35 years.
Eligibility
Sex
ALL
Min age
16 Years
Max age
35 Years
Healthy volunteers
Accepted
\*\*Inclusion Criteria:\*\*
* Male competitive soccer players aged 16-35 years.
* Regular participation in organized soccer training and competition.
* A minimum of 6 years of systematic soccer training experience.
* Participation in regular team training during the study period.
* Habitual mixed diet.
* Ability and willingness to maintain usual dietary habits and training load throughout the 4-week intervention.
* Written informed consent provided by the participant.
* For participants under 18 years of age, written informed consent provided by a parent or legal guardian and assent provided by the participant.
\*\*Exclusion Criteria:\*\*
* Current use of omega-3 fatty acid supplements or fish-oil products.
* Use of omega-3 supplements within the 3 months preceding enrollment.
* Known allergy or hypersensitivity to fish, seafood, fish oil, or any ingredient of the study supplements.
* Diagnosed cardiovascular, metabolic, endocrine, gastrointestinal, neurological, inflammatory, autoimmune, or hematological disease.
* Acute infection, injury, or illness that could affect participation in training or study assessments.
* Use of medications or dietary supplements that could influence lipid metabolism, inflammatory status, hormonal profile, blood coagulation, cognitive function, or physical performance.
* Regular use of anticoagulant or antiplatelet medication.
* Significant change in diet, training volume, or supplementation during the study period.
* Failure to comply with the supplementation protocol or attendance requirements.
* Participation in another clinical or nutritional intervention study during the study period.
Primary outcome measure(s)
Change in Omega Index — From enrollment to the end of 4-week supplementation The Omega-3 Index will be assessed in erythrocytes as the combined percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to total fatty acids in erythrocyte membranes. Blood samples will be collected at baseline and after the 4-week supplementation period. In addition to the Omega-3 Index, the erythrocyte fatty acid profile, including individual omega-3 and omega-6 fatty acids, arachidonic acid (AA), and trans fatty acids, will be assessed. Changes from baseline to the end of the 4-week intervention will be evaluated.
Trial sites (1)
Facility
City
Region
Status
Jerzy Kukuczka Academy of Physical Education in Katowice
Katowice
Mikolowska 72a
Recruiting
More The Jerzy Kukuczka Academy of Physical Education in Katowice trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.